Page 32 - Hematologic Malignancies News Today

The wide-ranging market information of the CAR-T Therapy Treatment Market report will surely grow business and improve return on investment (ROI). This market research report gives CAGR values along with their fluctuations for the specific forecast period. The market report has been prepared by taking into account s...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic...

AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of onco...

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that ...

Sierra Oncology Announces Abstracts Accepted for American Society of Clinical Oncology Annual Meeting News provided by Share this article independence and overall survival to be presented— SAN MATEO, Calif., May 19, 2021  May 19, 2021 - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced three abstracts have been accepted into the program for the 2021 Annual Meeting of the American So...

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021 -Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) who had progression of disease within 24 months of first line chemoimmunotherapy (POD24); overall response rate of 93% in non-POD24- -An 8% discontinuation rate was observed in the combined study population-...

Viracta Therapeutics to Host Key Opinion Leader Webinar Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial Event to take place on Thursday, May 20th at 2:00 PM ET News provided by Share this article Share this article SAN DIEGO, May 18, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opi...

Primary worldwide  Global Hematologic Malignancies  Market manufacturing companies, to specify, clarify and analyse the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for future. To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market. Does this report provide customization? Customization helps organizations gain insight into specific market segments and areas of intere...

Dr. Francisco M. Marty, a prominent infectious disease specialist at Brigham and Women’s Hospital and the Dana Farber Cancer Institute, died last week in the Dominican Republic when he suffered a fall while photographing a waterfall popular with tourists, according to published reports and his family.

share: This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Li...